North America Blood Glucose Monitoring Devices Market

The North America blood glucose monitoring devices market is projected to grow from USD 6.52 billion in 2025 to USD 9.93 billion in 2030, at a CAGR of 8.8% during the forecast period.

One of the major factors behind the growth of the blood glucose monitoring devices market in North America is the high and rising incidence of diabetes and prediabetes, which, in turn, is driven by sedentary lifestyles, rising obesity rates, unhealthy diets, and an aging population. In addition to strong awareness of diabetes treatment and early screening programs, demand is also supported by the widespread use of self-monitoring and continuous glucose monitoring (CGM) devices, enabled by advanced healthcare infrastructure and the growing adoption of digital and remote patient monitoring solutions. Nevertheless, market growth is constrained by the high price of advanced glucose monitoring systems and consumables, on the one hand, and by inconsistent reimbursement coverage and out-of-pocket cost burdens for some patient groups, especially among the uninsured, the underinsured, and price-sensitive populations in the region, on the other hand.

Prominent players in the North America blood glucose monitoring devices market include Abbott Laboratories (US), DexCom, Inc. (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), Sinocare (China), B. Braun SE (Germany), and Ascensia Diabetes Care Holdings AG (Switzerland).

To know about the assumptions considered for the study download the pdf brochure

In April 2025, DexCom, Inc. (US) announced that the US FDA had approved the DexCom G7 15-Day Continuous Glucose Monitoring System for use by people over the age of 18 with diabetes.

In June 2024, Abbott Laboratories (US) announced USFDA clearance for two new over-the-counter continuous glucose monitoring (CGM) systems, Lingo and Libre Rio, based on Abbott's world-leading FreeStyle Libre continuous glucose monitoring technology.

Abbott Laboratories (US) is a global healthcare leader operating in over 160 countries. Through its Medical Devices division, the company has built a strong presence in diabetes care, offering both continuous and traditional blood glucose monitoring solutions under the FreeStyle brand. Its flagship FreeStyle Libre system, comprising sensors, test strips, data management software, and related accessories, has revolutionized glucose tracking by providing real-time insights that improve diabetes management. Additionally, the launch of the Lingo continuous glucose monitoring system for broader health and wellness applications has further strengthened Abbott’s position as an innovation leader in the blood glucose monitoring devices market.

DexCom, Inc. (US) develops, manufactures, and commercializes real-time CGM systems that deliver continuous, actionable insights into glucose levels without routine fingersticks. Its flagship DexCom G6 and next-generation G7 systems, supported by integrated mobile applications and data platforms, enable improved glycemic control and patient engagement. With a strong global presence across North America and Europe, and expanding markets in the Asia Pacific region, DexCom has established itself as a key innovator and market leader in CGM solutions, driving advancements in digital health and diabetes care.

Medtronic (Ireland) has a diversified portfolio spanning cardiovascular, neuroscience, surgical, and diabetes care solutions. In diabetes management, the company develops and markets advanced insulin delivery systems integrated with continuous glucose monitoring (CGM) technologies. Its flagship MiniMed insulin pump series, paired with Guardian CGM sensors and intelligent insulin management software, enables real-time glucose tracking and automated insulin delivery to help patients achieve better glycemic control. With a strong footprint across North America, Europe, and emerging markets, Medtronic continues to drive innovation in diabetes care, advancing toward fully closed-loop systems and strengthening its position as a leader in the blood glucose monitoring devices market.

MARKET RANKING

In North America, the blood glucose monitoring market is moderately consolidated, with the top five players accounting for over 50% of total market revenue. Abbott Laboratories (US) leads the regional market, supported by strong adoption of its FreeStyle product portfolio—particularly the FreeStyle Libre CGM platform—alongside continuous innovation, broad payer coverage, and extensive penetration across hospitals, clinics, and homecare settings. Dexcom, Inc. (US) is another key competitor, driven by the widespread use of its G6 and G7 CGM systems, an emphasis on real-time data accuracy, and seamless integration with digital health ecosystems and insulin delivery devices. Medtronic plc (Ireland) maintains a substantial presence in North America through its MiniMed insulin pump systems and Guardian CGM sensors, with a strategic focus on advancing hybrid and fully closed-loop diabetes management solutions. F. Hoffmann-La Roche Ltd (Switzerland) holds a stable market position via its Accu-Chek blood glucose monitoring portfolio, supported by strong distribution networks, physician familiarity, and patient support programs across the US and Canada. While Sinocare (China) has limited penetration in the North American market compared with domestic incumbents, it is gradually expanding its presence through cost-competitive offerings and targeted distribution strategies, primarily within price-sensitive segments.

Related Reports:

North America Blood Glucose Monitoring Devices Market by Product Type (Self-monitoring, Professional Point of Care), Application (Diabetes Management, Health & Wellness Monitoring), Test Site, End User (Self/Homecare) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com